ArticleDrug design, development and therapy2019
The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease.
Article in Drug design, development and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07104786 (Effectiveness of Obeticholic Acid Versus Vitamin E in Patients of Non-alcoholic Fatty Liver Disease), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effectiveness of Obeticholic Acid Versus Vitamin E in Patients of Non-alcoholic Fatty Liver Disease
Who cites it
30 citing papers in PubMed, 46 citations in OpenAlex.
- The gut microbiome-bile acid-FXR interplay: a pivotal axis in metabolic and gastrointestinal diseases.Gut microbes · 2026Review
- Gut‑liver‑kidney axis: A systems biology framework for understanding and treating chronic kidney disease (Review).International journal of molecular medicine · 2026Review
- Evidence-Based Management of MASLD: GRADE Evaluation of Pharmacological Therapies.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Cholestatic and autoimmune liver diseases, bile duct injury, oxidative stress, and therapeutic strategies.Frontiers in physiology · 2026Review
- Emerging nanomedicine for liver diseases treatment.Journal of nanobiotechnology · 2025Review
- Gut-liver axis in diabetes: Mechanisms and therapeutic opportunities.World journal of gastroenterology · 2025Review
- Multifaceted Interactions Between Bile Acids, Their Receptors, and MASH: From Molecular Mechanisms to Clinical Therapeutics.Molecules (Basel, Switzerland) · 2025Review
- Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis.International journal of molecular sciences · 2025Review
- An insight on the additive impact of type 2 diabetes mellitus and nonalcoholic fatty liver disease on cardiovascular consequences.Molecular biology reports · 2025Review
- HIV and the gut: implications for HIV persistence, immune dysfunction and cure strategies.Frontiers in immunology · 2025Review
- Xiaohua Funing decoction ameliorates non-alcoholic fatty liver disease by modulating the gut microbiota and bile acids.Frontiers in microbiology · 2025Article
- Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease.Frontiers in microbiology · 2025Review
- Gut microbiome and metabolic-associated fatty liver disease: Current status and potential applications.World journal of hepatology · 2023Review
- Review
- Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease.International journal of molecular sciences · 2023Review
- Enhancing intestinal barrier efficiency: A novel metabolic diseases therapy.Frontiers in nutrition · 2023Review
- Targeting the gut microbiota and its metabolites for type 2 diabetes mellitus.Frontiers in endocrinology · 2023Review
- Dietary supplementation of porcine bile acids improves laying performance, serum lipid metabolism and cecal microbiota in late-phase laying hens.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2022Article
- The Microbiota and It's Correlation With Metabolites in the Gut of Mice With Nonalcoholic Fatty Liver Disease.Frontiers in cellular and infection microbiology · 2022Article
- Interventions for non-alcoholic liver disease: a gut microbial metabolites perspective.Therapeutic advances in gastroenterology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.